Biora Therapeutics, Inc. announced the appointment of Ariella Kelman, MD, as Chief Medical Officer. Dr. Kelman has a proven track record of leading global biopharmaceutical development, clinical trials, and regulatory strategies. Before joining Biora Therapeutics, Dr. Kelman led clinical development at Human Immunology Biosciences, a clinical-stage company focused on drug discovery and development for immune-mediated conditions.

Prior to that, she spent 15 years at Genentech/Roche where she led clinical development programs for several new medicines for adults and children with inflammatory autoimmune diseases and subsequently served as global head of bioethics for Roche. Previously, Dr. Kelman served for ten years as an attending physician in the Division of Immunology and Rheumatology at Stanford University Hospital. Dr. Kelman holds an MD from Tel Aviv University.

She completed her residency in internal medicine at Kaiser Hospitals in Los Angeles and Santa Clara and completed fellowships in rheumatology and clinical research at Stanford University Hospital.